To evaluate the effect of Fimarsartan on pharmacodynamics, pharmacokinetics, and the safety of warfarin in healthy male volunteers.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
15
Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
INR AUC, INRmax, INRtmax
Time frame: pre-dose, 6, 12, 24, 36, 48, 72, 96, 120, 144 h post-dose on 1 d, 11 d
AUClast, AUCinf, Cmax ,Tmax, CL/F of S-warfarin and R-warfarin
Time frame: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 h post-dose on 1 d, 11 d
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.